---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-045885"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T01:56:28.434916+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx Q2 revenue up 3% to $14M; GAAP net loss $3.9M, cuts FY2022 guidance

## Summary
- Revenue $14.0M (+3% YoY); gross margin improved to 64% from 59%.
- GAAP net loss $3.9M ($0.21 loss per share) vs net income $0.4M in Q2 2021.
- Non-GAAP net loss $0.7M ($0.04 loss per share) vs $1.8M income year ago.
- Updated FY2022 revenue outlook to $62-68M (1-11% growth), citing temporary industry headwinds.
- Closed EvinceMed acquisition in April; repurchased 232,745 shares under $20M buyback program.

## SEC filing metadata
- accession: 0001213900-22-045885
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390022045885/0001213900-22-045885-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390022045885/ea164085-8k_optimizerx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-045885
- JSON: https://secwatch.observer/filing/0001213900-22-045885.json
- Plain text: https://secwatch.observer/filing/0001213900-22-045885.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.